Evaluation of Therapeutic Target Gene Expression Based on Residual Cancer Burden Classification After Neoadjuvant Chemotherapy for HER2-Negative Breast Cancer

Yuko Takahashi, Takayuki Iwamoto, Yoko Suzuki, Yukiko Kajiwara, Minami Hatono, Takahiro Tsukioki, Kengo Kawada, Mariko Kochi, Hirokuni Ikeda, Tadahiko Shien, Naruto Taira, Junji Matsuoka, Hiroyoshi Doihara, Shinichi Toyooka

Research output: Contribution to journalArticle

Abstract

Patients with residual disease usually have a poor prognosis after standard neoadjuvant chemotherapy for breast cancer. We explored novel therapeutic targets and potential additional adjuvant treatments for patients with residual disease after standard neoadjuvant chemotherapy and found therapeutic targets by estrogen receptor status.

Original languageEnglish
JournalClinical Breast Cancer
DOIs
Publication statusAccepted/In press - Jan 1 2019

Fingerprint

Residual Neoplasm
Breast Neoplasms
Gene Expression
Drug Therapy
Estrogen Receptors
Therapeutics

Keywords

  • Gene expression
  • Hormone receptor positive
  • Residual tumor burden
  • Targeted therapy
  • Triple negative

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

@article{7b30469cad964eec9c5b9ce9c9313601,
title = "Evaluation of Therapeutic Target Gene Expression Based on Residual Cancer Burden Classification After Neoadjuvant Chemotherapy for HER2-Negative Breast Cancer",
abstract = "Patients with residual disease usually have a poor prognosis after standard neoadjuvant chemotherapy for breast cancer. We explored novel therapeutic targets and potential additional adjuvant treatments for patients with residual disease after standard neoadjuvant chemotherapy and found therapeutic targets by estrogen receptor status.",
keywords = "Gene expression, Hormone receptor positive, Residual tumor burden, Targeted therapy, Triple negative",
author = "Yuko Takahashi and Takayuki Iwamoto and Yoko Suzuki and Yukiko Kajiwara and Minami Hatono and Takahiro Tsukioki and Kengo Kawada and Mariko Kochi and Hirokuni Ikeda and Tadahiko Shien and Naruto Taira and Junji Matsuoka and Hiroyoshi Doihara and Shinichi Toyooka",
year = "2019",
month = "1",
day = "1",
doi = "10.1016/j.clbc.2019.07.001",
language = "English",
journal = "Clinical Breast Cancer",
issn = "1526-8209",
publisher = "Elsevier",

}

TY - JOUR

T1 - Evaluation of Therapeutic Target Gene Expression Based on Residual Cancer Burden Classification After Neoadjuvant Chemotherapy for HER2-Negative Breast Cancer

AU - Takahashi, Yuko

AU - Iwamoto, Takayuki

AU - Suzuki, Yoko

AU - Kajiwara, Yukiko

AU - Hatono, Minami

AU - Tsukioki, Takahiro

AU - Kawada, Kengo

AU - Kochi, Mariko

AU - Ikeda, Hirokuni

AU - Shien, Tadahiko

AU - Taira, Naruto

AU - Matsuoka, Junji

AU - Doihara, Hiroyoshi

AU - Toyooka, Shinichi

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Patients with residual disease usually have a poor prognosis after standard neoadjuvant chemotherapy for breast cancer. We explored novel therapeutic targets and potential additional adjuvant treatments for patients with residual disease after standard neoadjuvant chemotherapy and found therapeutic targets by estrogen receptor status.

AB - Patients with residual disease usually have a poor prognosis after standard neoadjuvant chemotherapy for breast cancer. We explored novel therapeutic targets and potential additional adjuvant treatments for patients with residual disease after standard neoadjuvant chemotherapy and found therapeutic targets by estrogen receptor status.

KW - Gene expression

KW - Hormone receptor positive

KW - Residual tumor burden

KW - Targeted therapy

KW - Triple negative

UR - http://www.scopus.com/inward/record.url?scp=85072644046&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85072644046&partnerID=8YFLogxK

U2 - 10.1016/j.clbc.2019.07.001

DO - 10.1016/j.clbc.2019.07.001

M3 - Article

AN - SCOPUS:85072644046

JO - Clinical Breast Cancer

JF - Clinical Breast Cancer

SN - 1526-8209

ER -